TVARDI THERAPEUTICS, INC. Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale
TVARDI THERAPEUTICS, INC. (TVRD) reported Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale of $0 for the 12-month period ending 2019-12-31, per its 10-K filed 2020-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale · last filed 2020-02-27
- TVARDI THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2019 was $0.00.
- TVARDI THERAPEUTICS, INC. other-than-temporary impairment loss, debt securities, available-for-sale for fiscal 2018 was $0.00.
| Period end | Other-than-temporary Impairment Loss, Debt Securities, Available-for-sale 12 month |
|---|---|
| 2019-12-31 | $0.00 10-K · filed 2020-02-27 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |